ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancer
Authors:
Open Access
- 9 May 2025
- journal article
- review article
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 86 (4) , 101788
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid CarcinomaJAMA Oncology, 2024
- Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid CarcinomaJAMA Oncology, 2024
- 1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinomaAnnals of Oncology, 2022
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket studyAnnals of Oncology, 2022
- 575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)Annals of Oncology, 2021
- Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019JAMA Oncology, 2020
- Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data BaseCancer, 2016
- Aggressive Palliation and Survival in Anaplastic Thyroid CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2015
- Thyroid cancer mortality and incidence: A global overviewInternational Journal of Cancer, 2014
- Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapyHead & Neck, 2010